メインコンテンツにスキップ
検索

Rajのコーナー：ブログの要約

Rajのコーナー：Expert strategies for streamlined drug development

Explore expert blog posts from Dr. Rajesh Krishna, Certara’s Senior Distinguished Scientist, on best practices for optimizing clinical development. From assessing druggability to making informed decisions, get insights that streamline innovation and reduce costs.

Rajesh Krishna, PhD, Global Head of Certara Centers of Excellence

最新のリソース

注目コンテンツ

All resources

米国FDAのモデルに基づく医薬品開発と対になったパイロットプログラムが治験依頼者を助ける方法

サターラのサービス、医薬品開発、早期臨床 - ブログ、モデルに基づく医薬品開発、前臨床 - ブログ、ブログ

Why FDA’s omaveloxolone approval for Friedreich’s ataxia matters

Clinical Pharmacology, Early clinical - Blog, Late clinical - blog, Rare and Neglected Diseases, Therapeutic Specialties, Blog

Key development considerations for cell therapies

Early clinical - Blog, Preclinical - Blog, Blog

臨床薬理学と薬物動態学の各チームが協力すべき理由

Certara Services, Clinical Pharmacology, Clinical Trials, Drug Development, Early clinical - Blog, Pharmacometrics, pre-update, Blog

Resmetirom: A pioneering NASH clinical program

Clinical Pharmacology, Drug Safety, pre-update, Regulatory, Blog

How does a clinical development plan help drug programs?

Clinical Trials, Drug Development, pre-update, Regulatory, Blog

Reflections on the New FDA Clinical Pharmacology Guidance for Antibody-Drug Conjugates

Clinical Pharmacology, Drug Development, FDA, pre-update, Raj Roundup - featured, Regulatory, Blog

希少疾患治療薬開発の課題と機会

pre-update, Rare Disease - featured, White Paper

バイオシミラーとは何ですか？また、どのように開発されるのですか？

pre-update, Blog

Understanding the Role of Your Discovery Asset’s Target Product Profile

Discovery - Blog, pre-update, Blog

希少疾患治療薬開発におけるシグナル検出を増加させる方法

pre-update, Rare and Neglected Diseases, Blog

Stop if you don’t have an unambiguous drug effect for your new molecular entity!

pre-update, Blog

お問合せはこちら


Powered by Translations.com GlobalLink Web Software